FDA grants expanded approval for Bristol Myers Squibb anemia therapy - NJBIZ

“The approval of Reblozyl in the first-line treatment of anemia for patients with lower-risk MDS represents a crucial step in making transfusion independence possible for more patients," said Tracey Iraca, executive director of the MDS Foundation.

U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis

FDA grants breakthrough designation to progressive pulmonary fibrosis treatment

FDA grants expanded approval for Bristol Myers Squibb anemia therapy - NJBIZ

BMS and Janssen's antithrombotic granted FDA fast track designation - PMLiVE

U.S. FDA Approves Bristol Myers Squibb's CAR T Cell Therapy Breyanzi® for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy

U.S. FDA Approves Bristol Myers Squibb's Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions

BMS Patient Assistance Foundation, PDF, Medicare (United States)

Latest Pharma News and Updates Novartis, Gilead, BMS, AstraZeneca

RWJBarnabas Health & Rendina Healthcare Real Estate break ground on RWJBarnabas Health Family Care & Wellness at the Monmouth Mall - NJBIZ

FDA OKs Bristol-Myers Squibb's Breyanzi To Treat Large-B-Cell Lymphoma

U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma